我院2007年洋葱伯克霍尔德菌的药敏试验结果和抗菌药物治疗分析

Susceptibility Test and Antibacterial Drug Therapy of Burkholderia Cepacia in Our Hospital in 2007

目的:监测我院临床分离的洋葱伯克霍尔德菌的耐药性并分析临床抗菌药物治疗方案,为临床医师和临床药师更好地治疗该菌引起的感染提供依据。方法:分析我院2007年分离的17株洋葱伯克霍尔德菌对12种抗菌药物的药敏试验结果和临床治疗方案及效果。结果:该菌在我院临床分离细菌的阳性检出率为0.45%。药敏试验结果显示,体外抗菌药物敏感率最高的为哌拉西林/他唑巴坦(88.2%),其次为头孢他啶(82.4%);对替卡西林/克拉维酸、替卡西林完全耐药。根据药敏试验结果选择抗菌药物治疗有效(复查未检出菌为标准)的有9例,占52.9%。结论:洋葱伯克霍尔德菌是一种重要的院内感染病原菌,该菌具有多重耐药性,治疗上可选用哌拉西林/他唑巴坦、头孢他啶。

OBJECTIVE： To monitor the resistance of clinically isolated Burkholderia cepacia and analyze its antibacterial drug therapy so as to provide reference for clinician and pharmacists in providing better treatment for the infection caused by Burkholderia cepacia. METHODS： The susceptibility test results of 17 strains of isolating Burkholderia cepacia to 12 antimicrobial agents isolated by our hospital in 2007 and the corresponding antibacterial therapeutic regimen were analyzed. RESULTS： The positive rate of Burkholderia cepacia in our hospital was 0.45%. The susceptibility test on Burkholderia cepacia showed that piperacillin / tazobactam had the highest susceptible rate with 88.2%, followed by ceftazidime at 82.4%, while Burkholderia cepacia was completely resistant to ticarcillin/clavulanic acid or ticarcillin. The antibacterial drug treatment based on susceptibility test was effective （defined as no Burkholderia cepacia was detected in the recheck） in 9 cases（52.9% ） CONCLUSION： Burkholderia cepaeia is an important kind of pathogenic bacteria in nosocomial infection, and it is multidrug resistant and preferably treated by piperacillin/tazobactam or eeftazidime.